Press Room

2017 CPhI Worldwide

Start
Tuesday, October 24, 2017 - 08:00
End
Thursday, October 26, 2017 - 18:00
Location: Frankfurt, Germany
Booth Number: 111F21

Hovione will be attending CPhI Worldwide 2017 in Frankfurt, Germany. An event that is considered the world's leading European pharmaceutical exhibition, which brings together more than 42,000 pharma industry professionals from 150+ countries.

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

 

the leader in spray drying | Hovione

Hovione, the Leader in Spray Drying

Combining the largest capacity, the best scale-up science and the most experienced team, you can trust Hovione to take your project from development to market.

  • Hovione offers a number of innovative Particle Engineering technologies, at all scales, to address challenges in drug delivery.
  • More than 13 years of expertise in commercial Spray Drying.
API Plus products | Hovione

API+

Enabling Novel Formulations Through Engineered Drug Product Intermediate

  • Targeted lung delivery
  • Taste masking
  • Controlled release
  • Modified solubility
  • Improved stability
  • Nanoparticles

The Experts in Customized API for Inhalation

Hovione is using its advanced technologies to enhance API's performance and offer a range of customized Drug Product Intermediates.

Hovione inhalation grade APIs are designed at the particle level to bring unique performance to your formulation.

hovione-customized-apis-for-inhalation

Hovione provides the peace of mind of a high quality manufacturer who is a founding member of Rx-360 and has an unblemished regulatory track record.

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

We look forward to meeting you at our booth # 111F21 at the Messe Frankfurt in Germany.

 

 

 

You might be also interested in:

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024